Skip to main navigation Skip to search Skip to main content

A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn's disease

  • William J. Sandborn
  • , Subrata Ghosh
  • , Julian Panes
  • , Ivana Vranic
  • , Wenjin Wang
  • , Wojciech Niezychowski
  • University of California at San Diego
  • University of Calgary
  • Institute of Health Carlos III (ISCIII)
  • Pfizer

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'A phase 2 study of Tofacitinib, an oral janus kinase inhibitor, inpatients with crohn's disease'. Together they form a unique fingerprint.
Sort by

Pharmacology, Toxicology and Pharmaceutical Science